

Mechanistic Prediction and validation of Brevilin A Therapeutic Effects in Lung Cancer

Ruixue Wang

Shandong University of Traditional Chinese Medicine

Cuiyun Gao

Binzhou Medical University Hospital

Meng Yu

Shandong University of Traditional Chinese Medicine

Jialing Song

Binzhou Medical University Hospital

Zhenzhen Feng

Binzhou Medical University Hospital

Ruyu Wang

Jiangxi University of Chinese Medicine

Huafeng Pan

Guangzhou University of Chinese Medicine

Haimeng Liu

Binzhou Medical University Hospital

Wei Li

Shandong University of Traditional Chinese Medicine

Xiangzhen Fan

643355196@qq.com

Shandong University of Traditional Chinese Medicine

Research Article

Keywords: Brevilin A, lung cancer, molecular mechanism, network pharmacology, molecular docking, experimental validation

Posted Date: March 6th, 2024

DOI: <https://doi.org/10.21203/rs.3.rs-3986795/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Additional Declarations: No competing interests reported.

Abstract

Background

Traditional Chinese medicine (TCM) has found widespread application in neoplasm treatment, yielding promising therapeutic candidates. Previous studies have revealed the anti-cancer properties of Brevilin A, a naturally occurring sesquiterpene lactone derived from *Centipeda minima* (L.) A.Br. (*C. minima*), a TCM herb, specifically against lung cancer. However, the underlying mechanisms of its effects remain elusive. This study employs network pharmacology and experimental analyses to unravel the molecular mechanisms of Brevilin A in lung cancer.

Methods

The Batman-TCM, Swiss Target Prediction, Phrammapper, SuperPred, and BindingDB databases were screened to identify Brevilin A targets. Lung cancer-related targets were sourced from GEO, Genecards, OMIM, TTD, and Drugbank databases. Utilizing Cytoscape software, a protein-protein interaction (PPI) network was established. Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), set enrichment analysis (GSEA), and gene-pathway correlation analysis were conducted using R software. To validate network pharmacology results, molecular docking, molecular dynamics simulations, and in vitro experiments were performed.

Results

We identified 599 Brevilin A-associated targets and 3864 lung cancer-related targets, with 155 overlapping genes considered as candidate targets for Brevilin A against lung cancer. The PPI network highlighted STAT3, TNF, HIF1A, PTEN, ESR1, and MTOR as potential therapeutic targets. GO and KEGG analyses revealed 2893 enriched GO terms and 157 enriched KEGG pathways, including the PI3K-Akt signaling pathway, FoxO signaling pathway, and HIF-1 signaling pathway. GSEA demonstrated a close association between hub genes and lung cancer. Gene-pathway correlation analysis indicated significant associations between hub genes and the cellular response to hypoxia pathway. Molecular docking and dynamics simulations confirmed Brevilin A's interaction with PTEN and HIF1A, respectively. In vitro experiments demonstrated Brevilin A-induced dose- and time-dependent cell death in A549 cells. Notably, Brevilin A treatment significantly reduced HIF-1 α mRNA expression while increasing PTEN mRNA levels.

Conclusions

This study elucidates the intricate molecular mechanisms responsible for the therapeutic effects of Brevilin A on lung cancer, providing a molecular foundation for future exploration of Brevilin A's therapeutic potential.

1. Introduction

Lung cancer is a common malignancy with high incidence and mortality worldwide[1]. Non-small cell lung cancer (NSCLC) accounts for approximately 80–85% of all lung cancer cases[2]. Despite considerable advancements in the prevention, early diagnosis, and treatment of NSCLC, the clinical outcomes for advanced NSCLC remain

suboptimal[3, 4]. Therefore, there exists an imperative requirement to innovate novel therapeutic strategies for the effective treatment of NSCLC[5].

Traditional Chinese medicine (TCM) has garnered attention as a promising avenue in cancer treatment, attributed to its commendable therapeutic efficacy and minimal side effects[6]. TCM products have demonstrated anticancer effects through diverse pathways and mechanisms[7]. Brevilin A, a sesquiterpene lactone derived from *C. minima*, exhibits a spectrum of pharmacological activities encompassing anti-cancer[8, 9], anti-oxidative[10], anti-inflammatory[11, 12], and immune-enhancing effects[13]. Previous studies have shown the potential of Brevilin A in combating various human malignancies, including lung cancer[14], nasopharyngeal carcinoma[15], multiple myeloma[16], gastric cancer[17], breast cancer[18], and prostate cancer[19]. A published study delineated that Brevilin A induces apoptosis in lung cancer cells by promoting reactive oxygen species (ROS) generation and inhibiting STAT3 activation[20]. However, the precise molecular mechanisms underlying Brevilin A's action against lung cancer remain elusive. Moreover, Brevilin A exhibits a favorable pharmacokinetic profile and remarkable bioavailability, with no discernible acute toxicity observed in mice administered a substantial dosage of Brevilin A[16]. This implies the safety of Brevilin A, thereby encouraging further exploration of its therapeutic potential in the context of lung cancer.

Network pharmacology is a robust bioinformatics tool for comprehensively identifying candidate targets, functions, and mechanisms of TCM in disease treatment[21]. In this study, we employed network pharmacology to predict the potential mechanisms of Brevilin A in lung cancer. Molecular docking and in vitro experiments were conducted to validate the obtained results. The workflow of this study is elucidated in Fig. 1.

2. Materials and methods

2.1 Retrieval of potential targets of Brevilin A

The identification of targets associated with the compound denoted as "Brevilin A" was accomplished through the application of the Bioinformatics Analysis Tool for the Molecular Mechanism of Traditional Chinese Medicine database, herein referred to as Batman-TCM (<http://bionet.ncpsb.org.cn/batman-tcm/index.php>), whereby targets achieving a score exceeding 5 were considered. The 3D structures and Isomeric SMILES of the aforementioned compound, Brevilin A, were procured from the PubChem database (<https://pubchem.ncbi.nlm.nih.gov/>). Utilizing the structural information of Brevilin A, prospective targets were elucidated through computational analyses conducted on multiple platforms, namely Swiss Target Prediction (<http://swisstargetprediction.ch/>), Phrammapper (<http://lilab-ecust.cn/phrammapper/index.html>), SuperPred (<https://prediction.charite.de/>), and BindingDB (<https://www.bindingdb.org/bind/index.jsp>) databases. The resultant target predictions underwent standardization procedures utilizing the UniProt database.

2.2 Screening for lung cancer-related targets

The keyword "Lung cancer" guided our exploration in the Gene Expression Database (GEO, <https://www.ncbi.nlm.nih.gov/geo/>), resulting in the retrieval of the GSE136043 dataset. Gene differential expressions (DEGs) in the dataset were then analyzed using the R package limma, wherein genes exhibiting log₂ (fold change) > 1 or < -1, coupled with a p-value < 0.05, were designated as differentially expressed. Concurrently, targets associated with lung cancer were ascertained through a comprehensive inquiry encompassing the Omim (<https://www.omim.org/>), GeneCards (<https://www.genecards.org/>), TTD (<https://db.idrblab.net/ttd/>), and Drugbank (<https://go.drugbank.com/>) databases. The outcomes from these diverse databases were

amalgamated, and duplicates were expunged, and the resulting targets underwent standardization employing the UniProt database. The identification of candidate targets linked to both the pharmaceutical agent denoted as "Brevilin A" and lung cancer was achieved through exploration of the Xiantao Academic website (<https://www.xiantaozi.com>).

2.3 Construction of protein-protein interaction (PPI) network

To ascertain information regarding interactions among proteins, data pertaining to candidate target genes were submitted to the esteemed STRING database (<https://string-db.org/>) [22]. The designated species for analysis was "Homo sapiens," and a minimum interaction score threshold of 0.400, denoting medium confidence, was applied. The outcomes were obtained in TSV format and imported into Cytoscape 3.7.2 for the purpose of visualizing the PPI network interactions. The utilization of the exceptional CytoHubba Cytoscape plugin facilitated the identification of pivotal genes within the PPI network. The Maximum Correlation Clique (MCC) for each node in the PPI network was calculated using the CytoHubba plugin, wherein larger and darker nodes indicated higher-scoring genes.

2.4 GO and KEGG pathway enrichment analysis

The R 4.3.1 software was employed to perform Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses, utilizing a $P\text{-value} < 0.05$ and $Q\text{-value} < 1$ as the criteria for selection. The GO enrichment analysis encompassed cellular components (CC), biological processes (BP), and molecular functions (MF). The eight most notable terms for each category have been delineated, and bubble diagrams were generated using the R 4.3.1 software. The KEGG enrichment analysis aimed to elucidate the potential mechanisms by which Brevilin A engages with lung cancer. Subsequently, bubble charts were generated to visually represent the top 20 significant pathways, employing the R 4.3.1 software.

2.5 GSEA enrichment analysis

To ascertain the association between key targets and potential mechanisms in lung cancer, Gene Set Enrichment Analysis (GSEA) was performed on the GSE136043 dataset using the R package "clusterProfiler," with a $P\text{-value} < 0.05$ employed as the filtering criterion.

2.6 Component-target molecular docking and molecular dynamics simulation

Molecular docking and molecular dynamics simulation represent computational techniques frequently utilized for the preliminary investigation of mechanisms and drug discovery. Their efficacy lies in their capacity to predict potential binding orientations and affinities of protein-ligand complexes [23, 24].

2.6.1 Molecular docking

In the preparatory phase, protein crystal structures were initially acquired from the Protein Data Bank (PDB, <https://www.rcsb.org/> (accessed on 12 September 2023)). Subsequently, homology modeling was employed for the reconstruction of missing residue structures, utilizing a previously established template with reference to the SWISS-MODEL website[25]. The molecular structure of Brevilin A was obtained from the PubChem database (<https://pubchem.ncbi.nlm.nih.gov/> (accessed on 12 September 2023)). Subsequent to acquisition, the molecular structure underwent geometry optimization employing the B3LYP approach and the 6-311 ++ G (d, p) basis set, utilizing Gaussian 09W and GaussView 05 software. The standard restrained electrostatic potential (RESP) of

Brevilin A was calculated and applied using the Multiwfn program[26]. Molecular docking was performed on the SwissDock website, employing default settings[27]. The resultant docking sites between the ligand and the protein were visualized using PyMOL and Discovery Studio 2019 software[28].

2.6.2 Molecular dynamics simulation

The optimal conformations derived from molecular docking underwent comprehensive evaluation of binding stability through molecular dynamics simulation, utilizing Gromacs 2020.06 software[29]. The simulations employed the AMBER99SB-ILDN/GAFF force field, and the initial systems were established in a cubic box featuring a 1.0 nm layer, populated with the TIP3P water model. Energy minimizations were performed using the steepest descent algorithm. Subsequently, the systems were equilibrated with the canonical (NVT) and isothermal-isobaric (NPT) ensembles for 100 ps prior to the commencement of the molecular dynamics simulation. The equilibrium system was configured to maintain a temperature of 310 K and a standard pressure of 1.0 bar. The ensuing molecular dynamics simulations spanned a duration of 50 ns to evaluate the stability of the complex. Trajectory files were employed to calculate the root mean square deviation (RMSD), root mean square fluctuation (RMSF), Radius of gyration (Rg) value, and solvent accessible surface area (SASA). These parameters were selected for their capacity to offer insights into the structural states of the complex. To ascertain the binding free energies (BFE) of the complex, the molecular mechanics/Poisson-Boltzmann surface area (MM/PBSA) approach was applied. The BFE in an aqueous solvent (ΔG_{bind}) is typically expressed as the sum of three components: (1) ΔE_{MM} , signifying the change in gas-phase molecular mechanics energy; (2) ΔG_{PB} , indicating the change in polar solvation energy; and (3) ΔG_{SA} , denoting the change in non-polar solvation energy. Additionally, the alteration in conformational entropy ($-T\Delta S$) was estimated using the interaction entropy (IE) method[30]. These calculations were performed using trajectory files at 1 ns intervals for the final 20 ns, during which the RMSD remained stable.

2.7 Gene-pathway correlation analysis

RNA-sequencing expression profiles (level 3) and pertinent clinical data for lung cancer were acquired from the TCGA dataset (<https://portal.gdc.com>). Analysis was conducted utilizing the GSVA package in R software, with the parameter method='ssgsea' being chosen. The examination of the relationship between genes and pathway scores was carried out using Spearman correlation. All analytical procedures and R packages were implemented using R version 4.3.1. A p-value less than 0.05 was considered statistically significant.

2.8 Experimental validation

2.8.1 Chemicals and reagents

Brevilin A with 99.71% purity and Cell Counting Kit-8 (CCK-8) kit were obtained from MCE (MedChemExpress, shanghai, China).

2.8.2 Cell culture

A549 cells were procured from the American Type Culture Collection (ATCC, Manassas, VA, USA) and subsequently cultivated in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS). All aforementioned reagents were acquired from Gibco (CA, USA). The cells were maintained in a humidified incubator with 5% CO₂ at a temperature of 37°C.

2.8.3 Cell viability assay

A549 cells were cultured in 96-well plates with a density of 4000 cells per well. After 24 hours of incubation, the cells were exposed to Brevilin A at specified concentrations for 24 and 48 hours. Subsequently, the cells were treated with CCK-8 solution for an additional hour at 37°C, and the absorbance was quantified at 450 nm using a microplate reader (ThermoFisher, Waltham, MA).

2.8.4 Quantitative RT-PCR (qRT-PCR)

RNA was isolated from cells using the NucleoSpin RNA isolation Kit (Macherey-Nagel, Düren, Germany) and TRIzol™ reagent, respectively. Subsequently, reverse transcription-PCR was conducted using the RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific, Waltham, USA) following the manufacturer's instructions. Quantitative PCR (qPCR) analysis was performed on the ABI 7500 Fast Real-time PCR System using the Taq pro Universal SYBR qPCR Master Mix (Vazyme Biotech, Nanjing, China). Relative gene expression was determined using the $\Delta\Delta C_t$ method, and the primer sequences are available upon request.

2.9 Statistical analysis

Statistical analyses were conducted using GraphPad Prism 8.0. The data presented in this study are derived from a minimum of three independent experiments and are expressed as the mean $\pm$ standard error of the mean (SEM). To assess differences, unpaired t-tests and one-way analysis of variance (ANOVA) were employed. P-values less than 0.05 were deemed statistically significant.

3. Results

3.1 PPI network analyses

A total of 2554 DEGs, comprising 1214 upregulated and 1340 downregulated genes, were identified and visually represented using a volcano plot (Fig. 2A) and a heatmap (Fig. 2B). Subsequently, we gathered 599 Brevilin A-related targets and 3864 lung cancer-related targets, resulting in 155 overlapping genes selected as Brevilin A candidate targets against lung cancer (Fig. 2C). A PPI network of the 155 overlapping targets was constructed, consisting of 151 nodes and 2134 edges (Fig. 3A, B). Nodes with higher degrees were considered more pivotal in the network. The top 30 genes, exhibiting the highest degree of connectivity, are presented in Table 1. Identified through MCC scores, STAT3, TNF, HIF1A, PTEN, ESR1, and MTOR were identified as potential hub genes (Fig. 3C).

Table 1
Degree of hub regulatory genes analyzed by Cytoscape.

Name	Symbol	Degree	Average Shortest PathLength	Betweenness Centrality	Closeness Centrality	Neighborhood Connectivity
Tumor necrosis factor	TNF	95	1.393333333	0.051584339	0.717703349	38.15789474
Signal transducer and activator of transcription 3	STAT3	92	1.413333333	0.038666898	0.70754717	40.08695652
Proto-oncogene tyrosine-protein kinase Src	SRC	88	1.44	0.070315983	0.694444444	38.20454545
Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN	PTEN	83	1.473333333	0.03764339	0.678733032	40.53012048
Hypoxia-inducible factor 1-alpha	HIF1A	83	1.48	0.036424015	0.675675676	41.46987952
Estrogen receptor	ESR1	81	1.493333333	0.043621748	0.669642857	40.01234568
Nuclear factor NF-kappa-B p105 subunit	NFKB1	80	1.506666667	0.032043207	0.663716814	41.475
G1/S-specific cyclin-D1	CCND1	75	1.56	0.023045173	0.641025641	42.12
Receptor tyrosine-protein kinase erbB-2	ERBB2	75	1.546666667	0.020795759	0.646551724	42.22666667
Prostaglandin G/H synthase 2	PTGS2	71	1.566666667	0.02182886	0.638297872	43
Interleukin-10	IL10	70	1.573333333	0.019330865	0.63559322	41.94285714
Toll-like receptor 4	TLR4	68	1.586666667	0.016253195	0.630252101	42.35294118
Serine/threonine-protein kinase mTOR	MTOR	67	1.58	0.045501984	0.632911392	44.37313433
Peroxisome proliferator-activated receptor gamma	PPARG	67	1.586666667	0.028081306	0.630252101	43.86567164
Insulin-like growth factor I	IGF1	67	1.58	0.021387304	0.632911392	45.85074627
C-C motif chemokine 2	CCL2	64	1.613333333	0.013568449	0.619834711	44.03125

Name	Symbol	Degree	Average Shortest PathLength	Betweenness Centrality	Closeness Centrality	Neighborhood Connectivity
Glycogen synthase kinase-3 beta	GSK3B	59	1.64	0.013339113	0.609756098	45.84745763
Interleukin-4	IL4	55	1.686666667	0.007190134	0.592885375	45.72727273
Tyrosine-protein kinase JAK2	JAK2	55	1.666666667	0.023161161	0.6	47.58181818
NAD-dependent protein deacetylase sirtuin-1	SIRT1	54	1.706666667	0.006113591	0.5859375	47.37037037
Hematopoietic progenitor cell antigen CD34	CD34	53	1.72	0.010031337	0.581395349	46.86792453
Bcl-2-like protein 1	BCL2L1	53	1.706666667	0.009762444	0.5859375	48.66037736
Angiotensinogen	AGT	52	1.686666667	0.061142799	0.592885375	40.94230769
Cyclin-dependent kinase inhibitor 1	CDKN1A	51	1.766666667	0.017783501	0.566037736	45.52941176
Phosphatidylinositol 3-kinase regulatory subunit alpha	PIK3R1	49	1.733333333	0.007475376	0.576923077	44.6122449
Platelet-derived growth factor receptor beta	PDGFRB	47	1.733333333	0.010130617	0.576923077	48.57446809
Cyclin-dependent kinase 4	CDK4	47	1.78	0.005998832	0.561797753	47.68085106
Forkhead box protein O3	FOXO3	46	1.766666667	0.004839212	0.566037736	48.73913043
Mitogen-activated protein kinase 14	MAPK14	45	1.76	0.005257046	0.568181818	50.75555556
Progesterone receptor	PGR	45	1.78	0.013641332	0.561797753	42.68888889

3.2 GO and KEGG function enrichment analysis

We conducted GO and KEGG function enrichment analyses on the 155 overlapping targets, resulting in the identification of 2893 GO terms and 157 KEGG pathways. The top 8 significant GO terms from each category are depicted in Fig. 4A. In the CC category, enrichments were observed in transferase complexes facilitating the transfer of phosphorus-containing groups, secretory granule lumen, and cytoplasmic vesicle lumen. In the BP category, enrichments included epithelial cell proliferation, positive regulation of kinase activity, and gland development. The MF category exhibited enrichments in DNA-binding transcription factor binding, RNA polymerase II-specific DNA-binding transcription factor binding, and protein tyrosine kinase activity (Fig. 4A). The top 20 significant pathways, such as the PI3K-Akt signaling pathway, FoxO signaling pathway, and HIF-1 signaling pathway, are presented in Fig. 4B and Table 2. A chord diagram was employed to visually depict the relationship

between enriched KEGG pathways and genes (Fig. 5A), while Fig. 5B illustrates the distribution of key targets in the HIF-1 signaling pathway.

Table 2
KEGG pathway enrichment analysis

ID	Description	P value	Padjust	Q value	Count
hsa04151	PI3K-Akt signaling pathway	1.05E-20	2.69E-18	1.09E-18	38
hsa01521	EGFR tyrosine kinase inhibitor resistance	3.92E-20	5.02E-18	2.04E-18	21
hsa05215	Prostate cancer	2.08E-19	1.77E-17	7.21E-18	22
hsa05205	Proteoglycans in cancer	3.62E-15	2.32E-13	9.44E-14	25
hsa04218	Cellular senescence	8.86E-15	4.54E-13	1.85E-13	22
hsa04068	FoxO signaling pathway	3.41E-14	1.45E-12	5.91E-13	20
hsa05212	Pancreatic cancer	7.86E-14	2.88E-12	1.17E-12	16
hsa05417	Lipid and atherosclerosis	1.01E-13	3.24E-12	1.32E-12	24
hsa04066	HIF-1 signaling pathway	1.75E-13	4.97E-12	2.02E-12	18
hsa05161	Hepatitis B	2.10E-13	5.38E-12	2.19E-12	21
hsa05163	Human cytomegalovirus infection	2.79E-13	6.50E-12	2.64E-12	24
hsa05230	Central carbon metabolism in cancer	3.72E-13	7.94E-12	3.23E-12	15
hsa05218	Melanoma	5.79E-13	1.06E-11	4.31E-12	15
hsa05223	Non-small cell lung cancer	5.79E-13	1.06E-11	4.31E-12	15
hsa05235	PD-L1 expression and PD-1 checkpoint pathway in cancer	1.07E-12	1.75E-11	7.13E-12	16
hsa05214	Glioma	1.10E-12	1.75E-11	7.13E-12	15
hsa05220	Chronic myeloid leukemia	1.35E-12	2.03E-11	8.25E-12	15
hsa05222	Small cell lung cancer	1.82E-12	2.59E-11	1.06E-11	16
hsa05221	Acute myeloid leukemia	3.41E-12	4.60E-11	1.87E-11	14
hsa04933	AGE-RAGE signaling pathway in diabetic complications	6.94E-12	8.89E-11	3.62E-11	16

3.3 GSEA enrichment analysis

To further elucidate the pathway analysis of DEGs, GSEA analysis was performed on both low and high expression of hub genes. The GSEA results are shown in Fig. 6, revealing that signaling pathways associated with the high expression phenotype of STAT3 encompass phagosome, protein processing in the endoplasmic reticulum, and viral carcinogenesis. Conversely, pathways linked to the low expression of STAT3 include neuroactive ligand – receptor interaction and olfactory transduction (Fig. 6A). For TNF, the high expression phenotype is correlated with pathways such as phagosome, protein processing in the endoplasmic reticulum, and lysosome, while the low expression is associated with neuroactive ligand – receptor interaction and olfactory transduction (Fig. 6B). HIF1A's high expression phenotype is linked to Epstein – Barr virus infection, lysosome, phagosome, and protein processing in the endoplasmic reticulum, while its low expression is tied to olfactory transduction (Fig. 6C). The pathways associated with high PTEN expression include focal adhesion, neuroactive ligand – receptor interaction, olfactory transduction, and the rap1 signaling pathway, while low PTEN expression is connected to the biosynthesis of amino acids (Fig. 6D). ESR1's high expression is associated with neuroactive ligand – receptor interaction, olfactory transduction, and the rap1 signaling pathway, while low ESR1 expression is linked to the biosynthesis of amino acids and protein processing in the endoplasmic reticulum (Fig. 6E). MTOR's high expression is connected to human T – cell leukemia virus 1 infection, protein processing in the endoplasmic reticulum, and viral carcinogenesis, whereas low MTOR expression is associated with neuroactive ligand – receptor interaction and olfactory transduction (Fig. 6F). These results underscore that the significantly enriched pathways associated with core targets align closely with those implicated in lung cancer. Notably, biosynthesis of amino acids, neuroactive ligand – receptor interaction, olfactory transduction, and protein processing in the endoplasmic reticulum emerge as pathways intricately associated with lung cancer (Fig. 7).

3.4 Gene-pathway correlation analysis

The Network Pharmacology results presented above indicate that HIF-1A stands out as one of the top three hub genes, and the HIF-1 signaling pathway emerges prominently as one of the most enriched pathways. The widely acknowledged centrality of the HIF-1 pathway in orchestrating cellular responses under conditions of hypoxia is highlighted [31]. In light of this recognition, we postulate that the hypoxic response and the hypoxia-related HIF-1 signaling pathway constitute crucial molecular mechanisms through which Brevilin A exerts its anti-lung cancer effects. Our exploration aimed to investigate the correlations between the hub genes and the cellular response to the hypoxia pathway. Remarkably, our findings align perfectly with our initial assumptions. All of the top six hub genes (STAT3, TNF, HIF1A, PTEN, and ESR1), with the exception of MTOR, demonstrated significant associations with the cellular response to the hypoxia pathway (Fig. 8).

3.5 Validation of molecular docking and molecular dynamics simulation

Building upon insights gleaned from prior investigations, the present study employed molecular docking and molecular dynamics simulation techniques to assess the binding mode and affinity of Brevilin A with HIF1A and PTEN targets. The outcomes of molecular docking are visually depicted in Fig. 9, encompassing both 2D and 3D representations. Additionally, Table 3 provides a succinct summary of fundamental information regarding binding mode and affinity. The results indicate robust bindings between Brevilin A and the respective targets, with binding affinities of -8.08 (HIF1A) and -7.46 (PTEN). Following this, optimal conformations underwent a 50 ns molecular dynamics simulation to evaluate the stability of the binding. As illustrated in Fig. 10A, the RMSD of the complexes

achieved stability at 20 ns, displaying minimal fluctuations, indicative of secure ligand binding to the target pockets. Subsequently, RMSF was computed to assess atom deviations within the proteins (Fig. 10B). The findings indicate that fluctuations primarily occurred at the terminals of the proteins, without compromising the integrity of the binding pocket.

Furthermore, the Rg value was employed to elucidate the conformational state of the proteins. As shown in Fig. 10C, proteins underwent a sequence of swelling and recovery prior to 20 ns, maintaining stability during the subsequent simulation period. An analysis of the SASA was conducted to assess the proteins' interaction capability with surrounding solvents throughout the simulations (Fig. 10D). The findings demonstrated a reduction in SASA, suggesting a gradual enhancement in the binding affinity between the ligand and proteins[32]. The MM/PBSA approach, a predominant method for reassessing binding affinity, facilitated the calculation of the BFE between the ligand and protein[33]. Analysis of the results revealed that Brevilian-A-HIF1A and Brevilian-A-PTEN exhibited BFEs of -40.431 kJ/mol and - 80.088 kJ/mol, respectively (**Table 4**), indicative of a robust binding affinity.

Table 3. The binding pose and energy between Brevilin A and the targets

Target	(PDB ID)	Compound	amino acid interactions	Affinity (kcal/mol)
HIF1A	4ZPR	Brevilin A	VAL191, HIS229, GLN299, TYR325; THR188, TRP189, LYS190, ILE227, GLY298, THR322, VAL323, ILE324,THR327 ;	-8.08
PTEN	1D5R	Brevilin A	PRO169, ARG173, TYR176, TYR177, LEU318, THR319; ARG172, VAL275, PHE279, ILE280, PRO283, GLU284, LEU320, THR321, ASP324;	-7.46

Table 4. MMPBSA (kJ/mol) of protein-ligand complex

Energy type	HIF1A-Brevilin A	PTEN-Brevilin A
MM	-127.584	-150.515
PB	77.87	75.138
SA	-18.554	-23.575
Total Binding Energy	-68.268	-98.951
TΔS	27.837	18.863
Total Binding Free Energy	-40.431	-80.088

3.6 Brevilin A-induced NSCLC cell death via targeting HIF-α pathway

To assess the impact of Brevilin A on lung carcinoma cells, we conducted a CCK-8 assay. Our results revealed that the administration of Brevilin A resulted in a dose- and time-dependent reduction in the viability of A549 cells (Fig. 11B, C). Following exposure to Brevilin A, there was a noticeable decrease in the quantity of adherent cells, accompanied by a morphological transformation characterized by a rounded appearance (Fig. 11D). These results

unequivocally demonstrate the pronounced cytotoxicity of Brevilin A towards NSCLC cells, consistent with the outcomes derived from network pharmacology.

To further validate the outcomes obtained through network pharmacology, we examined the mRNA expression level of HIF-1 α in A549 cells. Remarkably, Brevilin A treatment significantly reduced HIF-1 α expression in a dose-dependent manner ($p < 0.05$) (Fig. 11F). Additionally, exposure to Brevilin A led to a significant increase in PTEN mRNA levels ($p < 0.05$) (Fig. 11E). These findings indicate that Brevilin A potentially elicits apoptosis in NSCLC cells by targeting the HIF- α pathway, aligning with the network pharmacology results.

Discussion

Sesquiterpene lactones, derived from plants, are widely employed in TCM for their anti-inflammatory and anticancer properties[34]. These compounds exhibit reactivity with functional groups, notably the thiol group on proteins and enzymes. They demonstrate selectivity towards tumor and cancer stem cells by targeting specific signaling pathways, making them noteworthy agents in cancer clinical trials[35, 36]. Previous studies from our research group have established the neuroprotective effects of Brevilin A against lipopolysaccharide-induced neuroinflammation both in vitro and in vivo. In the present study, we elucidate the therapeutic efficacy of Brevilin A in the context of lung cancer, operating through multi-target, multi-biological processes, and multi-pathway mechanisms.

Our results highlight STAT3, TNF, HIF1A, PTEN, ESR1, and MTOR as potential therapeutic targets for Brevilin A's anticancer activity. STAT3, a transcription factor integral to diverse biological processes, including cell proliferation, survival, differentiation, and angiogenesis[37], has been implicated in various human cancers, such as head and neck tumors, cervical cancer, gastric carcinoma, and colon cancer[38–41]. Notably, exosome-mediated transfer of specific microRNAs has been associated with the activation of STAT3 signaling-induced epithelial-mesenchymal transition in lung cancer cells[42]. TNF- α , a member of the tumor necrosis factor superfamily, exhibits a spectrum of biological activities[43] and has been implicated in numerous human cancers, influencing processes such as growth, invasion, and metastasis[44, 45]. In NSCLC patients, elevated levels of IL-1, IL-6, and TNF- α have been linked to cancer pain and prognosis[46]. HIF (hypoxia-inducible factor)[47], a transcription factor crucial for tumor angiogenesis, cell survival, proliferation, apoptosis, metastasis, infiltration, and metabolism[48], plays a pivotal role in promoting lung cancer cell proliferation under conditions of chronic intermittent hypoxia[49]. Studies also demonstrate that certain formulations in TCM can inhibit NSCLC cell proliferation by downregulating HIF-1 α expression[50]. Phosphatase and tensin homolog deleted on chromosome ten (PTEN), encoding the classical PTEN protein with phosphatase activity, acts as a tumor suppressor by antagonizing the activity of tyrosine kinases and other phosphorylases. Meta-analyses indicate a correlation between PTEN and poor prognosis in lung cancer[51], and clinical studies confirm abnormal expression of EGFR, TGF- α , P-AKT, and PTEN in NSCLC patients[52], potentially contributing to NSCLC pathogenesis. In the present study, we utilized AutoDock Vina and PyMOL software to investigate Brevilin A's potential binding sites with these proteins, revealing robust binding activity. GSEA analysis further validated the strong association of these targets with lung cancer.

The GO and KEGG analyses revealed 2893 enriched GO terms and 157 enriched KEGG pathways, encompassing notable pathways such as the PI3K-Akt signaling pathway, FoxO signaling pathway, and HIF-1 signaling pathway. The PI3K-Akt signaling pathway, governing various cellular functions including growth, differentiation, proliferation, survival, motility, invasion, and intracellular trafficking, plays a pivotal role in tumorigenesis[53]. Studies have reported the induction of apoptosis and inhibition of invasion in NSCLC through the PI3K/Akt/mTOR signaling

pathway by compounds like Alopurinol[54]. Additionally, CAF-derived exosomes have been identified to promote NSCLC cellular proliferation and chemoresistance through regulation of the PTEN/PI3K-AKT signaling axis[55]. The FOXO signaling pathway, triggered by the PI3K/AKT pathway, is instrumental in mediating cell proliferation, differentiation, and tumorigenesis[56–58]. Inhibition of CCCTC-binding factor (CTCF) has been shown to regulate the FoxO signaling pathway, impeding tumor growth in vivo[59]. Notably, our study is the first to unveil that Brevilin A exerts anti-lung cancer effects by targeting the HIF-1 signaling pathway. Gene-pathway correlation analysis further revealed significant associations between most hub genes and the cellular response to hypoxia pathway. Hypoxia, influencing tumor signaling pathways through hypoxia-inducible factors (HIFs) and reducing free radical production, holds significance in tumor progression. Studies have demonstrated the role of hypoxia in activating EGFR and inducing resistance to gefitinib in EGFR-mutant non-small cell lung cancer[61]. Silencing HIF-1 α expression has been shown to significantly reduce the invasive ability of lung cancer cells under hypoxic conditions[62]. Molecular docking analysis and molecular dynamics simulation affirmed the robust interaction of Brevilin A with HIF1A and PTEN, respectively. In vitro experiments demonstrated that Brevilin A induces dose- and time-dependent cell death in A549 cells, concomitant with decreased HIF-1 α mRNA expression and increased PTEN mRNA levels. These results suggest the potential of the HIF-1 signaling pathway as a therapeutic target for Brevilin A in lung cancer treatment.

In summary, our study delineated the core targets and key pathways of Brevilin A in lung cancer through an integrated approach involving network pharmacology, molecular docking analysis, and experimental validation. The therapeutic effects of Brevilin A in lung cancer were demonstrated to involve a multi-target, multi-biological process, and multi-pathway mechanism, with noteworthy inhibition of the HIF-1 signaling pathway. These results lay a theoretical foundation for the prospective clinical application of Brevilin A. Nevertheless, it is imperative to acknowledge certain limitations in this study. Firstly, the utilization of more comprehensive databases would enhance the reliability of results. Secondly, further experimental validations are imperative to consolidate the findings derived from network pharmacology. Therefore, additional investigations are warranted to unravel the anti-lung cancer molecular mechanisms of Brevilin A.

Abbreviations

TCM

traditional Chinese medicine

C. minima

Centipeda minima (L.) A. Br. et Aschers

PPI

protein-protein interaction

GO

Gene Ontology

KEGG

Kyoto Encyclopedia of Genes and Genomes

GSEA

enrichment analysis

NSCLC

non-small cell lung cancer

DEGs

Gene differential expressions

MCC
Maximum Correlation Clique
CC
cellular component
BP
biological process
MF
molecular function
RESP
restrained electrostatic potential
RMSD
root mean square deviation
RMSF
root mean square fluctuation
Rg
Radius of gyration
SASA
solvent accessible surface area
BFE
binding free energies
MM/PBSA
molecular mechanics/Poisson-Boltzmann surface area
IE
interaction entropy.

Declarations

Consent for publication

Not applicable.

Data and materials availability

The datasets used and/or analyzed in the current study are available from the corresponding author upon reasonable request.

Competing interests

All authors declared that they have no conflicts of interest.

Author's contributions

RXW, CYG, XZF, WL and HML designed the project. RXW, CYG, MY, JLS, ZZF, RYW, HFP collected and analyzed the data. RXW and CYG performed the experiments. RXW, CYG, XZF, WL and HML wrote and revised the manuscript and provided consulting. All authors approved the final submitted manuscript.

Acknowledgments

This study was supported by the Natural Science Foundation of Shandong Province (grant no. ZR202111290609), the China Postdoctoral Science Foundation (grant no. 2023M732138), and the Science and Technology Project of Binzhou Medical University (grant no. BY2021KYQD33)

References

1. Sung H, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *Cancer J Clin*. 2021;71(3):209–49.
2. Han F, Li CF, Cai Z, et al. The critical role of AMPK in driving Akt activation under stress, tumorigenesis and drug resistance. *Nat Commun*. 2018;9(1):4728.
3. Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments. *Lancet*. 2017;389(10066):299–311.
4. Rodak O, Peris-Díaz MD, Olbromski M, Podhorska-Okolów M, Dzięgiel P. Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy. *Cancers (Basel)*. 2021;13(18):4705.
5. Imyanitov EN, Iyevleva AG, Levchenko EV. Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives. *Crit Rev Oncol Hematol*. 2021;157:103194.
6. Liu Y, Yang S, Wang K, et al. Cellular senescence and cancer: Focusing on traditional Chinese medicine and natural products. *Cell Prolif*. 2020;53(10):e12894.
7. Wang K, Chen Q, Shao Y, et al. Anticancer activities of TCM and their active components against tumor metastasis. *Biomed Pharmacother*. 2021;133:111044.
8. You P, Wu H, Deng M, Peng J, Li F, Yang Y. Brevilin A induces apoptosis and autophagy of colon adenocarcinoma cell CT26 via mitochondrial pathway and PI3K/AKT/mTOR inactivation. *Biomed Pharmacother*. 2018;98:619–25.
9. Ding Y, et al. Sesquiterpene Lactones Attenuate Paclitaxel Resistance Via Inhibiting MALAT1/STAT3/ FUT4 Axis and P-Glycoprotein Transporters in Lung Cancer Cells. *Front Pharmacol*. 2022;13:795613.
10. Wang J, Li M, Cui X, et al. Brevilin A promotes oxidative stress and induces mitochondrial apoptosis in U87 glioblastoma cells. *Onco Targets Ther*. 2018;11:7031–40.
11. B QQA et al. *Brevilin A inhibits NLRP3 inflammasome activation in vivo and in vitro by acting on the upstream of NLRP3-induced ASC oligomerization*. *Molecular immunology*. 135: p. 116–126.
12. Zhou YL, Yan YM, Li SY, et al. 6-O-angeloylplenolin exerts neuroprotection against lipopolysaccharide-induced neuroinflammation in vitro and in vivo. *Acta Pharmacol Sin*. 2020;41(1):10–21.
13. Zhu X, Liu F, Wu Q, et al. Brevilin A enhances innate immunity and the resistance of oxidative stress in *Caenorhabditis elegans* via p38 MAPK pathway. *Int Immunopharmacol*. 2022;113:109385. Pt A).
14. Chen X, Du Y, Nan J, et al. Brevilin A, a novel natural product, inhibits janus kinase activity and blocks STAT3 signaling in cancer cells. *PLoS ONE*. 2013;8(5):e63697.
15. Liu R, Qu Z, Lin Y, Lee CS, Tai WC, Chen S. Brevilin A Induces Cell Cycle Arrest and Apoptosis in Nasopharyngeal Carcinoma. *Front Pharmacol*. 2019;10:594.
16. Liu Y, Chen XQ, Liang HX, et al. Small compound 6-O-angeloylplenolin induces mitotic arrest and exhibits therapeutic potentials in multiple myeloma. *PLoS ONE*. 2011;6(7):e21930.

17. Lee D, Kwak HJ, Kim BH, et al. Brevilin A Isolated from *Centipeda minima* Induces Apoptosis in Human Gastric Cancer Cells via an Extrinsic Apoptotic Signaling Pathway. *Plants (Basel)*. 2022;11(13):1658.
18. Qu Z, Lin Y, Mok DK, Bian Q, Tai WC, Chen S. Brevilin A, a Natural Sesquiterpene Lactone Inhibited the Growth of Triple-Negative Breast Cancer Cells via Akt/mTOR and STAT3 Signaling Pathways. *Onco Targets Ther*. 2020;13:5363–73.
19. You P, Tang L, Zhu Y, Tian Y. Brevilin A shows an anti-tumor role in prostate cancer via the lncRNA H19/miR-194/E2F3 signaling pathway. *Aging*. 2023;15(10):4411–28.
20. Khan M, Maryam A, Saleem MZ, et al. Brevilin A induces ROS-dependent apoptosis and suppresses STAT3 activation by direct binding in human lung cancer cells. *J Cancer*. 2020;11(13):3725–35.
21. Silverman EK, Schmidt HHHW, Anastasiadou E, et al. Molecular networks in Network Medicine: Development and applications. *Wiley Interdiscip Rev Syst Biol Med*. 2020;12(6):e1489.
22. Hsia CW, Ho MY, Shui HA, Tsai CB, Tseng MJ. Analysis of dermal papilla cell interactome using STRING database to profile the ex vivo hair growth inhibition effect of a vinca alkaloid drug, colchicine. *Int J Mol Sci*. 2015;16(2):3579–98.
23. Meng XY, Zhang HX, Mezei M, Cui M. Molecular docking: a powerful approach for structure-based drug discovery. *Curr Comput Aided Drug Des*. 2011;7(2):146–57.
24. Filipe HAL, Loura LMS. Molecular Dynamics Simulations: Advances and Applications. *Molecules*. 2022;27(7):2105.
25. Waterhouse A, Bertoni M, Bienert S, et al. SWISS-MODEL: homology modelling of protein structures and complexes. *Nucleic Acids Res*. 2018;46(W1):W296–W303.
26. Lu T, Chen F. Multiwfn: a multifunctional wavefunction analyzer. *J Comput Chem*. 2012;33(5):580–92.
27. Grosdidier A, Zoete V, Michielin O. SwissDock, a protein-small molecule docking web service based on EADock DSS. *Nucleic Acids Res*. 2011;39(Web Server issue):W270–7.
28. Seeliger D, de Groot BL. Ligand docking and binding site analysis with PyMOL and Autodock/Vina. *J Comput Aided Mol Des*. 2010;24(5):417–22.
29. Van Der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE, Berendsen HJ. GROMACS: fast, flexible, and free. *J Comput Chem*. 2005;26(16):1701–18.
30. Duan L, Liu X, Zhang JZ, Interaction Entropy. A New Paradigm for Highly Efficient and Reliable Computation of Protein-Ligand Binding Free Energy. *J Am Chem Soc*. 2016;138(17):5722–8.
31. Semenza GL. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. *J Clin Invest*. 2013;123(9):3664–71.
32. Li X, Miao F, Xin R, et al. Combining network pharmacology, molecular docking, molecular dynamics simulation, and experimental verification to examine the efficacy and immunoregulation mechanism of FHB granules on vitiligo. *Front Immunol*. 2023;14:1194823.
33. Genheden S, Ryde U. The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. *Expert Opin Drug Discov*. 2015;10(5):449–61.
34. Dong Y, Qian X, Li J. Sesquiterpene Lactones and Cancer: New Insight into Antitumor and Anti-inflammatory Effects of Parthenolide-Derived Dimethylaminomicheliolide and Micheliolide [retracted in: *Comput Math Methods Med*. 2023;2023:9856528]. *Comput Math Methods Med*. 2022;2022:3744837.
35. Ghantous A, Gali-Muhtasib H, Vuorela H, Saliba NA, Darwiche N. What made sesquiterpene lactones reach cancer clinical trials? *Drug Discov Today*. 2010;15(15–16):668–78.

36. Babaei G, Aliarab A, Abroon S, Rasmi Y, Aziz SG. Application of sesquiterpene lactone: A new promising way for cancer therapy based on anticancer activity. *Biomed Pharmacother*. 2018;106:239–46.
37. Hanlon MM, Rakovich T, Cunningham CC, et al. STAT3 Mediates the Differential Effects of Oncostatin M and TNF α on RA Synovial Fibroblast and Endothelial Cell Function. *Front Immunol*. 2019;10:2056.
38. Masuda M et al. *Constitutive Activation of Signal Transducers and Activators of Transcription 3 Correlates with Cyclin D1 Overexpression and May Provide a Novel Prognostic Marker in Head and Neck Squamous Cell Carcinoma*. *Cancer research*, 2015. 2002.62(12): p. 3351–3355.
39. Takemoto S, Ushijima K, Kawano K, et al. Expression of activated signal transducer and activator of transcription-3 predicts poor prognosis in cervical squamous-cell carcinoma. *Br J Cancer*. 2009;101(6):967–72.
40. Kim DY, Cha ST, Ahn DH, et al. STAT3 expression in gastric cancer indicates a poor prognosis. *J Gastroenterol Hepatol*. 2009;24(4):646–51.
41. Kusaba T, Nakayama T, Yamazumi K, et al. Activation of STAT3 is a marker of poor prognosis in human colorectal cancer. *Oncol Rep*. 2006;15(6):1445–51.
42. Zhang X, Sai B, Wang F, et al. Hypoxic BMSC-derived exosomal miRNAs promote metastasis of lung cancer cells via STAT3-induced EMT. *Mol Cancer*. 2019;18(1):40.
43. Tseng WC, Lai HC, Huang YH, Chan SM, Wu ZF. Tumor Necrosis Factor Alpha: Implications of Anesthesia on Cancers. *Cancers (Basel)*. 2023;15(3):739.
44. Suganuma M, et al. Human gastric cancer development with TNF- α -inducing protein secreted from *Helicobacter pylori*. *Cancer Lett*. 2012;322(2):133–8.
45. Zhao P, Zhang Z. TNF- α promotes colon cancer cell migration and invasion by upregulating TROP-2. *Oncol Lett*. 2018;15(3):3820–7.
46. Liu Y, Gao Y, Lin T. *Expression of interleukin-1 (IL-1), IL-6, and tumor necrosis factor- α (TNF- α) in non-small cell lung cancer and its relationship with the occurrence and prognosis of cancer pain*. *Annals of Palliative Medicine*, 2021. 10(12): p. 12759–12766.
47. Zimna A, Kurpisz M. Hypoxia-Inducible Factor-1 in Physiological and Pathophysiological Angiogenesis: Applications and Therapies. *Biomed Res Int*. 2015;2015:549412.
48. Yang SL, Ren QG, Wen L, Hu JL. Clinicopathological and prognostic significance of hypoxia-inducible factor-1 α in lung cancer: a systematic review with meta-analysis. *J Huazhong Univ Sci Technolog Med Sci*. 2016;36(3):321–7.
49. Hao S, Li F, Jiang P, Gao J. Effect of chronic intermittent hypoxia-induced HIF-1 α /ATAD2 expression on lung cancer stemness. *Cell Mol Biol Lett*. 2022;27(1):44.
50. Zhang W, Tian W, Wang Y et al. Explore the mechanism and substance basis of Mahuang FuziXixin Decoction for the treatment of lung cancer based on network pharmacology and molecular docking. *Comput Biol Med*. 2022;151(Pt A):106293.
51. Gu J, Ou W, Huang L, et al. PTEN expression is associated with the outcome of lung cancer: evidence from a meta-analysis. *Minerva Med*. 2016;107(5):342–51.
52. Yun F, Jia Y, Li X, et al. Clinicopathological significance of PTEN and PI3K/AKT signal transduction pathway in non-small cell lung cancer. *Int J Clin Exp Pathol*. 2013;6(10):2112–20.
53. Alzahrani AS. PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside. *Semin Cancer Biol*. 2019;59:125–32.

54. Liu F, Liu T, Li H. Alopentine inhibits the progression of non-small-cell lung cancer through the PI3K/Akt signaling pathway. *Cancer Cell Int.* 2021;21(1):662.
55. Shi L, Zhu W, Huang Y, et al. Cancer-associated fibroblast-derived exosomal microRNA-20a suppresses the PTEN/PI3K-AKT pathway to promote the progression and chemoresistance of non-small cell lung cancer. *Clin Transl Med.* 2022;12(7):e989.
56. Kousteni S. FoxO1: A molecule for all seasons. *J Bone Miner Res.* 2011;26(5):912–7.
57. Ho KK, Myatt SS, Lam EW. Many forks in the path: cycling with FoxO. *Oncogene.* 2008;27(16):2300–11.
58. Shan Z, Li Y, Yu S, et al. CTCF regulates the FoxO signaling pathway to affect the progression of prostate cancer. *J Cell Mol Med.* 2019;23(5):3130–9.
59. Shan Z, Li Y, Yu S, et al. CTCF regulates the FoxO signaling pathway to affect the progression of prostate cancer. *J Cell Mol Med.* 2019;23(5):3130–9.
60. Hu H, Zhang XW, Li L, et al. Inhibition of autophagy by YC-1 promotes gefitinib induced apoptosis by targeting FOXO1 in gefitinib-resistant NSCLC cells. *Eur J Pharmacol.* 2021;908:174346.
61. Minakata K, Takahashi F, Nara T, et al. Hypoxia induces gefitinib resistance in non-small-cell lung cancer with both mutant and wild-type epidermal growth factor receptors. *Cancer Sci.* 2012;103(11):1946–54.
62. Shyu KG, Hsu FL, Wang MJ, Wang BW, Lin S. Hypoxia-inducible factor 1alpha regulates lung adenocarcinoma cell invasion. *Exp Cell Res.* 2007;313(6):1181–91.

Figures




Figure 1

Mechanistic insights into Brevilin A action against lung cancer. Schematic diagram summarizing the mechanisms underlying Brevilin A action against lung cancer using network pharmacology, molecular docking, and experimental validation.




Figure 2

Differential gene expression analysis. (A) GEO Volcano Map and (B) GEO heatmap. Red and blue dots indicate up-regulated and down-regulated genes, respectively. (C) Venn diagram showing the overlap of Brevilin A-associated targets and lung cancer-related genes.




Figure 3

Protein-protein interaction (PPI) network analysis. (A) The PPI network. (B) Interaction between these genes. (C) Hub genes identified using the MCC method.




Figure 4

Functional enrichment analysis. Bubble chart of GO (A) and KEGG (B) function enrichment analysis.




Figure 6

GSEA enrichment plot of hub genes.




Figure 7

GSEA enrichment plot of GSE136043 dataset.




Figure 8

Correlation analysis of hub genes and cellular response to hypoxia pathway. * $p < 0.05$, ** $p < 0.01$, **** $p < 0.0001$.




Figure 9

Molecular docking results. (A) The binding mode of Brevilin A-HIF1A complex. (B) The binding mode of Brevilin A-PTEN complex. The 3D visualization is on the left, and the 2D visualization is on the right.




Figure 10

MD simulation analysis. (A) RMSD quantifying the deviation of complexes coordinates from the initial frame. (B) RMSF of individual protein atoms. (C) Rg for visualization of protein compactness. (D) SASA analysis of protein contact area with surrounding solvents.




Figure 11

Brevilin A-induced A549 cell death via targeting HIF-1α pathway. (A) The chemical structure of the Brevilin A. CCK8 assay in A549 cells treated with Brevilin A for 24 h (B) and 48 h (C). (D) Photographs of A549 cells after treatment for 24 h and 48 h. (E) mRNA expression levels of PTEN and HIF-1α in A549 cells treated with Brevilin A for 24 h. * $p < 0.05$, ** $p < 0.01$, **** $p < 0.0001$ versus vehicle control group.